Reaction
Renal Cell Carcinoma Stage Iv reporting signals
As of the last recalculation, Renal Cell Carcinoma Stage Iv appears in 113 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 165.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sorafenib | 16 | 165.1 | 165.3 |
| Sunitinib Malate | 26 | 157.9 | 158.0 |
| Pazopanib Hydrochloride | 19 | 155.3 | 155.4 |
| Axitinib | 8 | 81.3 | 81.4 |